XML 39 R26.htm IDEA: XBRL DOCUMENT

Collaboration Agreements (Tables)

3 Months Ended

Mar. 31, 2026

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Schedule Of Cost Sharing Payments And Reimbursements

Cost sharing payments to collaboration partners recorded as expenses in research and development expenses in the Condensed Consolidated Statements of Operations and Comprehensive Loss, and cost sharing reimbursements from collaboration partners recorded as an offset to expense in research and development expenses in the Condensed Consolidated Statements of Operations and Comprehensive Loss are as follows (in thousands):


	Three Months Ended March 31,
	2026		2025
Takeda Collaboration Agreement:
PTV:PGRN cost sharing (reimbursements)	$	(1,617)	$	(1,511)
ATV:TREM2 cost sharing (reimbursements)	—		(152)
Total Takeda cost sharing (reimbursements)(1)	(1,617)		(1,663)
Biogen Collaboration Agreement: LRRK2 cost sharing payments(2)	3,863		4,651
Net cost sharing payments (reimbursements)	$	2,246	$	2,988

_________________________________

(1)Cost sharing reimbursements of $1.6 million and $1.6 million were recorded as a receivable within prepaid expenses and other current assets on the Condensed Consolidated Balance Sheets as of March 31, 2026 and December 31, 2025, respectively.

(2)Cost sharing payments due to Biogen of $3.9 million and $2.8 million were recorded within other accrued costs and current liabilities on the Condensed Consolidated Balance Sheets as of March 31, 2026 and December 31, 2025, respectively.